Lineage Cell Therapeutics has a total of 859 patents globally, out of which 398 have been granted. Of these 859 patents, more than 41% patents are active. United States of America is where Lineage Cell Therapeutics has filed the maximum number of patents, followed by Australia and countries of Europe, it has generated an annual revenue of $3.89 million in the year 2021. Parallelly, the USA seems to be the main focused R&D centre and is also the origin country of Lineage Cell Therapeutics.
Lineage Cell Therapeutics was founded in the year 1990 by Judith Segall, Michael D West and Paul Segall. The firm is a clinical-stage biotechnology firm focused on creating innovative cell treatments to address unmet medical needs. As of April 2022, Lineage Cell Therapeutics has a market cap of $0.23 Billion.
Do read about some of the most popular patents of Lineage Cell Therapeutics which have been covered by us in this article and also you can find Lineage Cell Therapeutics’ patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Lineage Cell Therapeutics’ patent portfolio.
How many patents does the CEO of Lineage Cell Therapeutics have?
The CEO, Brian Culley, has 3 patents.
How many patents does Lineage Cell Therapeutics have?
Lineage Cell Therapeutics has a total of 859 patents globally. These patents belong to 123 unique patent families. Out of 859 patents, 360 patents are active.
How Many Patents did Lineage Cell Therapeutics File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Lineage Cell Therapeutics Applications Filed | Lineage Cell Therapeutics Patents Granted |
| 2011 | 25 | 16 |
| 2012 | 26 | 20 |
| 2013 | 20 | 19 |
| 2014 | 11 | 19 |
| 2015 | 61 | 33 |
| 2016 | 54 | 16 |
| 2017 | 37 | 31 |
| 2018 | 45 | 15 |
| 2019 | 17 | 28 |
| 2020 | 19 | 18 |
| 2021 | 16 | 20 |
| 2022 | – | 3 |
How many Lineage Cell Therapeutics patents are Alive/Dead?
Worldwide Patents
How Many Patents did Lineage Cell Therapeutics File in Different Countries?
Countries in which Lineage Cell Therapeutics Filed Patents
| Country | Patents |
| United States Of America | 218 |
| Australia | 96 |
| Europe | 75 |
| Japan | 72 |
| Canada | 57 |
| Singapore | 49 |
| Israel | 48 |
| United Kingdom | 40 |
| China | 34 |
| Hong Kong (S.A.R.) | 31 |
| Korea (South) | 23 |
| Germany | 20 |
| India | 13 |
| Spain | 9 |
| Brazil | 4 |
| Eurasian | 4 |
| Mexico | 3 |
| Philippines | 2 |
| Denmark | 2 |
| South Africa | 2 |
| New Zealand | 2 |
| Czech Republic | 1 |
| Yugoslavia/Serbia and Montenegro | 1 |
| Argentina | 1 |
Where are Research Centres of Lineage Cell Therapeutics Patents Located?
10 Best Lineage Cell Therapeutics Patents
US6800480B1 is the most popular patent in the Lineage Cell Therapeutics portfolio. It has received 425 citations so far from companies like Reliance Life Sciences, Geron Corporation, and Industrial Technology Research.
Below is the list of 10 most cited patents of Lineage Cell Therapeutics:
| Publication Number | Citation Count |
| US6800480B1 | 425 |
| US20030224411A1 | 397 |
| US6642048B2 | 375 |
| US20020072117A1 | 373 |
| US6458589B1 | 320 |
| US6833269B2 | 278 |
| US7326572B2 | 239 |
| US7033831B2 | 232 |
| US6506574B1 | 160 |
| US6440735B1 | 151 |
Which Companies are using Lineage Cell Therapeutics Patents to Advance their Research?
If patents or patents from a particular technology area of a company receive a lot of citations, it implies that the technology is being followed and incrementally innovated by the citing companies. It also indicates that citing companies are working on similar and closely related technologies.
The top citing companies in the Lineage Cell Therapeutics patent portfolio are Asterias Biotherapeutics, Procella Therapeutics, and Kaneka Corporation.
List of the top forward citing Companies –
| Company | Number of Patents |
| Procella Therapeutics Ab | 1 |
| Asterias Biotherapeutics | 1 |
| The Brigham And Women’S Hospital Inc | 1 |
| Accelerated Biosciences Corp | 1 |
| Cambridge Enterprise Limited | 1 |
| Regenerative Research Foundation | 1 |
| City Of Hope | 1 |
| StemRD | 1 |
| Corning | 1 |
| Kaneka Corporation | 1 |
Count of 102 and 103 Type Rejections based on Lineage Cell Therapeutics Patents
Top Lineage Cell Therapeutics Patents used in Rejecting Most Patent Applications
| Patent Number | Count of Rejected Applications |
| US20060194321A1 | 4 |
| US20050095708A1 | 2 |
| US20040253721A1 | 2 |
| US8148151B2 | 1 |
| US20180325958A1 | 1 |
| US6875607B1 | 1 |
| US7604990B2 | 1 |
| US20090263835A1 | 1 |
| US20100248366A1 | 1 |
| US20160362661A1 | 1 |
The firm is working on anti-ageing technology and is backed by BlackRock, Raffles Capital Management, Wells Fargo, and others.
EXCLUSIVE INSIGHTS COMING SOON!
What are Lineage Cell Therapeutics’ key innovation segments?